We are determined to realize the potential of modified universal donor RBCs to treat disease.

We are a biotechnology company that has developed an innovative approach to induce the proliferation of blood progenitor cells allowing us to produce large quantities of red blood cells (RBCs). This process has unlocked the potential to produce modified RBC with specialized properties to treat various diseases. Universal Cell Therapeutics is pushing the boundaries of biotechnology to unlock the potential of combining molecular genetics, stem cell biology and the human immune system to fight disease in new ways.

Our Core technology has been published in the peer reviewed journal BMC Biotechnology